German China

Cell Culture Automation Revolutionary Acoustic Technology Can Move Cells

Source: Press release University of Bristol 2 min Reading Time

Related Vendor

A spinout company from the University of Bristol, Impulsonics is developing a unique biotech platform for cell culture automation by making use of acoustic manipulation to help automate a number of the processes for scientists which are currently time-consuming and expensive.

Impulsonics team members Amanda Franklin, Luke Cox, and Ximena Vasto.(Source:  Impulsonics)
Impulsonics team members Amanda Franklin, Luke Cox, and Ximena Vasto.
(Source: Impulsonics)

Bristol/UK – Set up by Dr Luke Cox, Dr Amanda Franklin, Dr James Armstrong and Professors Bruce Drinkwater and Anthony Croxford, Impulsonics is a spinout company which developed out of the Ultrasonics & NDT Group at the University of Bristol.

Despite advances in biotechnology, cell culture automation remains a highly manual field. By utilizing acoustic manipulation, the Impulsonics team are developing a unique biotech platform which will help automate a number of the processes for scientists which are currently time-consuming and expensive.

Impulsonics’ technology will enable a massive reduction in complexity of key processes for researchers studying cells, and in turn will enable low cost, highly efficient systems for critical pain points such as cell passaging (the highly repetitive process where cells which have filled their current container must be moved to a new one).

This will enable a transformation of lab-scale cell culture techniques into a reliable industrial process suitable for 21st century healthcare and drug discovery applications.

This will be especially critical given the rise of AI in drug discovery which demands large volumes of high quality data, far beyond what current processes can yield.

“This is a really exciting time for us,” said Dr Luke Cox, CEO and Co-Founder of Impulsonics. "We're already seeing a demand for more reliable, scalable processes across the sector and that is exactly what our technology promises to deliver. Our unique approach builds on well-established industrial technologies from the aerospace and infrastructure sectors and will help to re-imagine workflows in biotechnology.”

Impulsonics has received investment from SFC Capital, British Business Investments, the University of Bristol and private angels. The funding will enable Impulsonics to accelerate development and testing, boosting the company’s mission to turn pioneering scientific innovations into scalable approaches for research and healthcare.

“There’s never been a more exciting time in biotechnology,” said SFC Investment Executive Ed Stevenson, “and Impulsonics fills a critical gap of scalability in a way that nobody else is tackling it. We were impressed by their innovative approach and are excited to be backing Luke and the team on their journey.”

(ID:50022685)

Subscribe to the newsletter now

Don't Miss out on Our Best Content

By clicking on „Subscribe to Newsletter“ I agree to the processing and use of my data according to the consent form (please expand for details) and accept the Terms of Use. For more information, please see our Privacy Policy. The consent declaration relates, among other things, to the sending of editorial newsletters by email and to data matching for marketing purposes with selected advertising partners (e.g., LinkedIn, Google, Meta)

Unfold for details of your consent